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Congenital malaria (CM) is believed to be rare due to belief that physical barrier of placenta to infected red cells, passive transfer of maternal antimalarial antibodies, and 
poor plasmodial replication in low free oxygen tension in fetal 
hemoglobin protect a neonate from acquiring malarial infection. 
Congenital malaria is defined as malaria acquired by the fetus 
or newborn from the mother, either in utero or at parturition. 
However there is no consensus on application of this definition. It 
can also be defined as the presence of asexual malaria parasites in 
the erythrocytes of newborns aged <7 days [1-3]. However, recent 
cross-sectional studies suggest the prevalence of 10.8-54.2% 
in the endemic areas [3,4]. The placental barrier does not seem 
to be very effective in preventing transplacental transmission 
of maternal malarial infection to the neonate in non-immune 
mothers. However, in 93% of such neonates, spontaneous clearing 
of infection takes place [2].
A study from India showed a lower incidence of CM 
29/1000 live births [4,5]. CM is an important cause of abortions, 
miscarriage, stillbirths, premature births, intrauterine growth 
restriction, and neonatal deaths [6]. However, placental infection 
occurs in as many as one-third of women who acquire an infection 
during pregnancy. While CM due to Plasmodium falciparum 
is frequently reported from the African continent, Plasmodium 
vivax CM is reported from Southeast Asia and India sporadically. 
Here, we report one case of CM due to P. vivax.
CASE REPORT
Our case was a 7-day-old term appropriate for gestational age 
male baby, weighing 2.4 kg (birth weight 2.5 kg) admitted to 
neonatal intensive care unit with the history of refusal to feed, 
marked pallor, and yellowish discoloration of eyes for 3 days. He 
was delivered by normal vaginal delivery at a government hospital 
and was hospitalized there for 5 days for birth asphyxia (APGAR 
was not documented). His clinical examination revealed heart 
rate of 140/min, respiratory rate of 55/min, temperature 98.4°F 
(by rectal), and capillary refill time <2 s. He had severe pallor, 
and icterus was present till legs and there were no dysmorphic 
features. On systemic examination, splenomegaly 3 cm below 
costal margin was present and the rest of systemic examination 
findings were within normal limits.
His primigravida mother had a history of moderate grade 
pyrexia with chills and anemia for 2 weeks in the last trimester for 
which she received therapy from some practitioner. There was no 
history of multiple vaginal examinations, leaking or foul smelling 
discharge/abortions/still births, or antepartum hemorrhage in the 
past. Her peripheral blood examination did not show any evidence 
of parasitemia.
On laboratory investigations, his hemoglobin was 9.7 g/dl, total 
leukocyte counts were 9360/mm3, platelets were 0.14 lacks/mm3, 
and random blood sugar was 42 mg/dl. His serum bilirubin 
was 22.8 mg/dl with an indirect fraction of 7 mg/dl and direct 
fraction of 5.8 mg/dl. Peripheral smear examination revealed 
P. vivax parasite trophozoites. Card test was positive for P. vivax 
antigen. His C-reactive protein was elevated (88.4 mg/dl), but 
blood culture was sterile. Serology for toxoplasmosis, rubella, 
cytomegalovirus, herpes simplex, and HIV was negative. The 
baby was managed with IV artesunate 3 mg/kg/day for 6 days 
along with supportive therapy of IV antibiotics, IV fluids, platelet 
and packed cell transfusion, and phototherapy. His condition 
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improved with regression of spleen, liver, pallor, and icterus. 
Repeat peripheral smear examination after therapy showed no 
hemoparasite. He was discharged after 7 days of hospitalization.
DISCUSSION
Lack of consensus on definition of CM and variety of definitions 
of CM and neonatal malaria has resulted in researchers reporting 
the different prevalence of the illness. We considered the 
definition of CM as the presence of asexual stages of malarial 
parasite in cord blood smear at delivery or peripheral blood 
smear of the neonate in first 7 days of life, irrespective of clinical 
symptoms [2]. The heavily parasitized placenta can result in 
transplacental transmission of malarial parasite (MP) both 
in cases of falciparum and vivax malaria [7,8]. The pregnant 
women in the endemic areas may experience heavy parasitemia, 
fever, severe anemia, abortions, stillbirths, and heavy placental 
parasitization [9]. Higher parasitemia is noted in cord blood 
as compared to neonatal blood [10]. Therefore, one must keep 
this condition in mind in unimmunized or semi-immune mother 
traveling to endemic zones. CM does not seem to be a rare disease 
as previously thought.
The onset of CM usually occurs at 10-30 days after birth, 
coinciding with the estimated half-life of maternal immunoglobulin 
in the neonate. Predominant clinical features include fever, 
anemia, and splenomegaly in the majority of cases. Other clinical 
features include poor feeding, regurgitation, diarrhea, drowsiness, 
restlessness, cyanosis, jaundice, and hepatomegaly. Maternal 
history suggestive of residing in the endemic zone, present or 
past malarial infection, stillbirths, abortions, HIV infections, 
and low-birth-weight babies should raise suspicion about this 
condition. The neonate may be symptomatic even on the 1st day 
of life. The delayed presentation may be due to fetal hemoglobin, 
abnormal hemoglobin resistant to malarial infections, and partial 
antimalarial chemotherapy during pregnancy.
Diagnosis of CM is established by microscopic identification 
of organism on Giemsa-stained thin and thick smear of cord blood 
or neonatal peripheral smear. The diagnosis of CM is frequently 
missed due to the limited sensitivity of light microscopy and 
additional investigations such as plasmodial antigen detection 
and polymerase chain reaction of blood may be necessary to 
arrive at diagnosis [11].
In the USA, whether symptomatic or not babies born to 
non-immune mothers with malaria are treated with quinine. 
Chloroquine-resistant babies have shown a good response to 
sulfadoxine-pyrimethamine combinations. Another regime 
approved in the USA is quinine plus clindamycin in both P. vivax 
and P. falciparum malarial infections [1]. In India, CM babies 
generally do not respond to chloroquine but respond well to oral 
and IV artesunate. IV artesunate is recommended as the drug of 
choice in all cases of severe malaria including young children. 
Primaquine is not required in infants with CM with P. vivax, but 
infected mothers can be treated with it after excluding G6PD 
deficiency [3,12,13].
CONCLUSION
CM prevalence should not be underestimated in the endemic 
zones, and a high index of suspicion should be kept in mothers 
and neonates with relevant risk factors. As clinical features of 
CM resemble with neonatal sepsis, malarial screening of febrile 
neonates especially in the endemic zone is suggested.
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